This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

STREAM trial - discontinuing statins in older adults without cardiovascular disease

Authoring team

  • the STREAM trial was an international, open-label, randomized, controlled trial evaluating whether discontinuing statin therapy in older adults with multimorbidity but no known cardiovascular disease is noninferior to continuing therapy
  • background: whether discontinuing statin therapy in older adults with at least two chronic conditions and no history of cardiovascular disease affects time to a first cardiovascular event or death had not been well characterized

Study Design and Population

  • population: 1880 community-dwelling adults aged 70 years or older (mean age 77.5 years, 46.9% women) taking statins for primary prevention with at least two chronic conditions
  • intervention: participants were randomly assigned in a 1:1 ratio to either discontinue (n=938) or continue (n=942) statin therapy and other lipid-lowering therapies
  • primary outcome: a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or death from any cause, whichever occurred first
  • noninferiority criteria: assessed on the basis of the between-group difference in restricted mean event-free survival time at 2 years, using a predefined noninferiority margin of −5.2 weeks

Key Findings and Results

  • primary outcome noninferiority: the between-group difference in restricted mean event-free survival time at 2 years was −2.0 weeks (95% CI, −3.7 to −0.3; p<0.001 for noninferiority), satisfying the predefined noninferiority threshold
  • event rates: over a median follow-up of 103 weeks (approximately 2 years), primary outcome events occurred in 119 participants (12.7%) in the discontinuation group compared to 87 participants (9.2%) in the continuation group
  • safety and serious adverse events: at least one serious adverse event occurred in 43.0% of participants in the discontinuation group and in 39.8% of participants in the continuation group

Primary Care Takeaway

  • among older adults (aged 70 years and older) with multimorbidity (at least two chronic conditions) receiving statins for primary prevention, discontinuing statins was noninferior to continuing treatment regarding 2-year major cardiovascular events or all-cause mortality
  • provides supportive clinical evidence for shared decision-making, polypharmacy management, and rational deprescribing of primary prevention statins in older patients

Reference:

  • Rodondi N, Haller ML, Bardoczi JB, Adam L, Blum MR, Gencer B, et al., for the STREAM Investigators. Discontinuing statins in older adults without cardiovascular disease. N Engl J Med. 2026;395:NEJMoa2606634.

 


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page